Opinion|Videos|June 27, 2024

Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

Author(s)Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc, Richardo D. Parrondo, MD

Key opinion leaders are introduced and present a concise overview of the topics to be addressed.

Episodes in this series

5 KOLs are featured in this panel.

EP. 1 Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

5 KOLs are featured in this panel.

EP. 2 Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

5 KOLs are featured in this panel.

EP. 3 Frontline BTKi Selection

5 KOLs are featured in this panel.

EP. 4 Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

5 KOLs are featured in this panel.

EP. 5 Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

5 KOLs are featured in this panel.

EP. 6 Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

5 KOLs are featured in this panel.

EP. 7 EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

5 KOLs are featured in this panel.

EP. 8 Navigating Treatment Approaches for R/R CLL

5 KOLs are featured in this panel.

EP. 9 How Experts View MAIC Data That was Presented at EHA 2024

5 KOLs are featured in this panel.

EP. 10 BTKi Intolerance in Real-world Practice & Management Strategy

5 KOLs are featured in this panel.

EP. 11 Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

5 KOLs are featured in this panel.

EP. 12 Approach to Hypertension Management With BTKi Treatment

5 KOLs are featured in this panel.

EP. 13 Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

5 KOLs are featured in this panel.

EP. 14 Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

A panel of 5 experts on CLL

EP. 15 Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

A panel of 5 experts on CLL

EP. 16 TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

A panel of 5 experts on CLL

EP. 17 EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

A panel of 5 experts on CLL

EP. 18 Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

A panel of 5 experts on CLL

EP. 19 Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

A panel of 5 experts on CLL

EP. 20 Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

A panel of 5 experts on CLL

EP. 21 Clinical Pearls and Impacts to Practice from EHA 2024

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, gastric cancer, gastrointestinal stromal tumor, renal cell carcinoma, and chronic lymphocytic leukemia.

August 30th, 2026

Five Under 5: Top Oncology Videos for the Week of 8/23

The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

The OncFive: Top Oncology Articles for the Week of 8/30

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC